
A look back on what's happened in optometry during the week of February 25-March 2.

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."

Shalu Pal, BSc, OD, FAAO, shares key takeaways from the contact lens zpanel discussion she participated in.

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key highlights from his portion of the "Presbyopia management panel," during SECO 2023 in Atlanta.

BRIM Biotechnology’s BRM421 is a first-in-class regenerative peptide and could relieve signs and symptoms of dry eye disease in as little as 2 weeks.

First 1-Day Lens that combines DigitalBoost and Aquaform technologies designed to deliver comfort for ‘always on’ digital lifestyles

Investigators evaluated and compared the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed between 2 hydrophobic acrylic intraocular lenses (IOLs).

One-day continuing education session offers latest insights and advancements.

Smaller corneal incisions made during cataract surgery are linked with better visual outcomes and less frequent postoperative endophthalmitis.

As efforts continue across the globe, optometrists need to take action in clinics.

See the results from our recent poll!

Supplementing vision care with nutrition may protect ocular tissues.

A look back on what's happened in optometry during the week of February 18-February 23.

The FDA issued an update to the warning issued early in February and recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment, and the firm agreed to initiate a recall.

The Biologics License Application for aflibercept 8 mg was supported by positive data from the PULSAR study, investigating wet AMD, and the PHOTON study, investigating DME.

Arjan Hura, MD, gives a sneak peek of the 17th annual Controversies in Modern Eye Care meeting being held this April in Los Angeles.


A PDUFA goal date of October 22, 2023 was assigned to the investigational eye drop candidate for the treatment of presbyopia.

Eye care providers need to look beyond visual acuity in screening for keratoconus.

Contoured prism lenses may resolve symptoms such as neck, shoulder, and head pain.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

Jason Romero, a legally blind ultra-runner, will be giving the keynote address at the 2023 Vision Expo East meeting March 16-19 in New York City.

A look back on what's happened in optometry during the week of February 11-February 16.

The eye care community is moving toward a more disruption-resistant system of care, from wearable tech to VEGF-eluting implants.

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

The next-generation compound of atropine does not contain preservatives or boric acid and can be stored at room temperature for up to 180 days.

The Biosciences group of the Centre for Ocular Research and Education (CORE) determined protein deposits on rigid gas permeable contact lens via radioactive counts by using a radiolabeled lysozyme in an artificial tear solution.

Vote in our most recent poll!

Patrick Mooney, CEO of SpyGlass Pharma, sits down to discuss the 6-month first-in-human clinical trial data of their drug delivery platform with bimatoprost, which is implanted during routine cataract surgery.

Medical and surgical technological advances show promise for future glaucoma management.